Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model A multistate model for Ewing sarcoma

被引:19
|
作者
Bosma, S. E. [1 ]
Rueten-Budde, A. J. [2 ]
Lancia, C. [2 ]
Ranft, A. [3 ,4 ]
Dirksen, U. [3 ,4 ]
Krol, A. D. [5 ]
Gelderblom, H. [6 ]
van de Sande, M. A. J. [1 ]
Dijkstra, P. D. S. [1 ]
Fiocco, M. [2 ,7 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthoped, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Math Inst, Leiden, Netherlands
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Sarcoma Ctr,German Canc Consortium,Pediat 3, Essen, Germany
[4] German Canc Consortium DKTK, Essen, Germany
[5] Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Med Stat Biomed Data Sci, Leiden, Netherlands
基金
欧盟第七框架计划;
关键词
Ewing sarcoma; multistate model; personalized medicine; prediction; survival; PROGNOSTIC-FACTORS; CHEMOTHERAPY; TUMORS; BONE; EXPERIENCE; SURVIVAL; ADJUVANT; SURGERY; THERAPY; PROGRAM;
D O I
10.1002/pbc.27943
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We investigated the effects of surgical margins, histological response, and radiotherapy on local recurrence (LR), distant metastasis (DM), and survival in Ewing sarcoma. Procedure Disease evolution was retrospectively studied in 982 patients with Ewing sarcoma undergoing surgery after chemotherapy using a multistate model with initial state surgery, intermediate states LR, pulmonary metastasis (DMpulm), other DM +/- LR (DMother), and final state death. Effect of risk factors was estimated using Cox proportional hazard models. Results The median follow-up was 7.6 years (95% CI, 7.2-8.0). Risk factors for LR are pelvic location, HR 2.04 (1.10-3.80), marginal/intralesional resection, HR 2.28 (1.25-4.16), and radiotherapy, HR 0.52 (0.28-0.95); for DMpulm the risk factors are <90% necrosis, HR 2.13 (1.13-4.00), and previous pulmonary metastasis, HR 4.90 (2.28-8.52); for DMother are 90% to 99% necrosis, HR 1.56 (1.09-2.23), <90% necrosis, HR 2.66 (1.87-3.79), previous bone/other metastasis, HR 3.08 (2.03-4.70); and risk factors for death without LR/DM are pulmonary metastasis, HR 8.08 (4.01-16.29), bone/other metastasis, HR 10.23 (4.90-21.36), and <90% necrosis, HR 6.35 (3.18-12.69). Early LR (0-24 months) negatively influences survival, HR 3.79 (1.34-10.76). Once DMpulm/DMother arise only previous bone/other metastasis remain prognostic for death, HR 1.74 (1.10-2.75). Conclusion Disease extent and histological response are risk factors for progression to DM or death. Tumor site and surgical margins are risk factors for LR. If disease progression occurs, previous risk factors lose their relevance. In case of isolated LR, time to recurrence is important for decision-making. Radiotherapy seems protective for LR especially in pelvic/axial. Low percentages of LR in extremity tumors and associated toxicity question the need for radiotherapy in extremity Ewing sarcoma.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Development and characterization of Ewing Sarcoma lung metastasis model
    Dasgupta, Atreyi
    Kurenbekova, Lyazat
    Patel, Tajhal
    Yustein, Jason T.
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Risk Factors for Metastasis at Initial Diagnosis With Ewing Sarcoma
    Ye, Conglin
    Dai, Min
    Zhang, Bin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [3] Patterns and quantitation of migration and metastasis in a zebrafish xenograft model of ewing sarcoma
    Anderson, Rebecca A.
    Cuervas-Mon, Usua Oyarbide
    Corey, Seth
    CLINICAL CANCER RESEARCH, 2022, 28 (18)
  • [4] Local recurrence of Ewing sarcoma: Is wide excision an acceptable treatment?
    Xue, Ruifeng
    Lewis, Valerae O.
    Moon, Bryan S.
    Lin, Patrick P.
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (04) : 746 - 752
  • [5] Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma
    Lin, Patrick P.
    Jaffe, Norman
    Herzog, Cynthia E.
    Costelloe, Colleen M.
    Deavers, Michael T.
    Kelly, Jeana S.
    Patel, Shreyaskumar R.
    Madewell, John E.
    Lewis, Valerae O.
    Cannon, Christopher P.
    Benjamin, Robert S.
    Yasko, Alan W.
    CANCER, 2007, 109 (03) : 603 - 611
  • [6] Prognostic factors for local and distant control in Ewing sarcoma family of tumors
    Rodriguez-Galindo, C.
    Navid, F.
    Liu, T.
    Billups, C. A.
    Rao, B. N.
    Krasin, M. J.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 814 - 820
  • [7] A tissue engineered model of Ewing's sarcoma
    Ludwig, Joseph A.
    Cherradi, Salah Lamhamedi
    Menegaz, Brian
    Santoro, Marco
    Mikos, Antonios
    CANCER RESEARCH, 2015, 75
  • [8] Risk of Recurrence and Survival After Relapse in Patients With Ewing Sarcoma
    Stahl, Martin
    Ranft, Andreas
    Paulussen, Michael
    Boelling, Tobias
    Vieth, Volker
    Bielack, Stefan
    Goertitz, Irene
    Braun-Munzinger, Gabriele
    Hardes, Jendrik
    Juergens, Heribert
    Dirksen, Uta
    PEDIATRIC BLOOD & CANCER, 2011, 57 (04) : 549 - 553
  • [9] Primary Ewing sarcoma of the larynx with distant metastasis: a case report and review of the literature
    Maroun, C. A.
    Khalifeh, I
    Tfayli, A.
    Moukarbel, R., V
    CURRENT ONCOLOGY, 2019, 26 (04) : E574 - E577
  • [10] Ewing's sarcoma with distant metastasis: A brief note on management and emerging therapies
    Meshram, Girish Gulab
    Kaur, Neeraj
    Hura, Kanwaljeet Singh
    CLINICS AND PRACTICE, 2019, 9 (03) : 87 - 89